Sunshine Biopharma (SBFM) Cash from Operations Growth (3y) (2014 - 2026)
Sunshine Biopharma (SBFM) Cash from Operations Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.15 Bn | 39.49 Bn | 2.15 Bn | 8.25% |
| 3 | Zoetis | 31.52 Bn | 29.84 Bn | 1.05 Bn | 52.97% |
| 4 | Takeda Pharmaceutical | 28.58 Bn | 22.78 Bn | 5.10 Bn | 5.90% |
| 5 | United Therapeutics | 22.16 Bn | 19.50 Bn | 683.80 Mn | 43.42% |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | -10.08% |
| 7 | Neurocrine Biosciences | 15.48 Bn | 15.09 Bn | 935.80 Mn | -8.76% |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 65.60% |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Sunshine Biopharma | 1.52 Mn | -12.23 Mn | 2.43 Mn | 37.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 37.60% |
| Mar 31, 2026 | -3.85% |
| Dec 31, 2025 | 10.40% |
| Sep 30, 2025 | 13.48% |
| Jun 30, 2025 | -31.08% |
| Mar 31, 2025 | -9.13% |
| Dec 31, 2024 | -121.79% |
| Sep 30, 2024 | -31.19% |
| Jun 30, 2024 | -94.85% |
| Mar 31, 2024 | -120.44% |
| Dec 31, 2023 | -85.16% |
| Sep 30, 2023 | -55.95% |
| Jun 30, 2023 | -258.47% |
| Mar 31, 2023 | -290.65% |
| Dec 31, 2022 | -159.99% |
| Sep 30, 2022 | -135.05% |
| Jun 30, 2022 | -129.51% |
| Mar 31, 2022 | -77.31% |
| Dec 31, 2021 | -39.07% |
| Sep 30, 2021 | -52.06% |